Supernus Pharmaceuticals SUPN Accounts payable and other current liabilities
Accounts payable and other current liabilities at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's accounts payable and other current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's accounts payable and other current liabilities?
- Supernus Pharmaceuticals (SUPN) reported accounts payable and other current liabilities of $49K in Q1 2026.
- How has Supernus Pharmaceuticals's accounts payable and other current liabilities changed year-over-year?
- Supernus Pharmaceuticals's accounts payable and other current liabilities decreased by 98.8% year-over-year, from $3.94M to $49K.
- What is the long-term trend for Supernus Pharmaceuticals's accounts payable and other current liabilities?
- Over 4 years (2021 to 2025), Supernus Pharmaceuticals's accounts payable and other current liabilities has grown at a 7.8% compound annual growth rate (CAGR), from $18.18M to -$24.57M.